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BIOMARKERS OF MILD COGNITIVE 
IMPAIRMENT AND ALZHEIMER’S DISEASE 
FIELD OF THE INVENTION 
The present invention relates to the ?eld of detection and of 
monitoring treatment of neurodegenerative disorders, includ 
ing Alzheimer’s disease and mild cognitive impairment 
(MCI). More particularly, the present invention relates to 
proteinaceous biomarkers that can be measured in biological 
?uids, Which can be used to aid in the detection of neurode 
generative disorders, including Alzheimer’ s disease and mild 
cognitive impairment. 
BACKGROUND OF THE INVENTION 
Alzheimer’s disease (AD), an age-associated dementing 
disorder, currently affects 4 million Americans and is the 
fourth leading cause of death in the US. The prevalence ofAD 
doubles every 5.1 years from 1% of Americans ages 65-69 to 
~39% of Americans age 90-95 (Jorm et al. Acta Psychiat 
Scand 761465-79 (1987). With aging of the “baby boom” 
generation, the largest segment of the US population, there 
may be 14 million Americans With AD by 2040 unless pre 
ventative strategies are developed. With a mean survival time 
of 8.1 years and a range of 1 to 25 years AD is a groWing 
socio-economic and medical problem With an estimated cost 
of 100 billion dollars per year in the US alone. 
Risk factors associated With AD include aging, presence of 
APOE-4 alleles, family history, head injury, loW educational 
attainment and loW linguistic ability early in life. Although 
mutations in presenilin 1 and 2 and the amyloid precursor 
protein (APP) are associated With familial AD (FAD) these 
cases account for less than 5% of all AD subjects. Currently, 
there are no knoWn genetic mutations associated With spo 
radic AD. 
Pathologically, the AD brain is characterized by a loss of 
total brain Weight, neuron loss and shrinkage, synapse loss, 
neuropil thread formation, abundance of neuro?brillary 
tangles (N FT) and senile plaques (SP) and by a proliferation 
of reactive microglia and astrocytes in particular brain 
regions including the hippocampus, amygdala and nucleus 
basalis of Meynert (nbM). 
The tWo hallmark pathologic markers of AD examined at 
autopsy are NET and SP. NFT are intracellular deposits of 
hyperphosphorylated tau, a microtubule associated protein in 
neuronal axons. The normal function of tau is to bind tubulin 
in axonal microtubules and promote stabilization (Goedert et 
al. EMBO J 81393-99 (1989), Buee et al. Brain Res Brain Res 
Rev 33195-130 (2000)). As such, tau is essential for axonal 
function and transport. Tau has 30 potential phosphorylation 
sites (Iqbal et al. J Neural Transm Suppl 621309-319 (2002); 
Buee et al. Brain Res Brain Res Rev 33195-130 (2000) and 
abnormal phosphorylation is observed in AD NFT leading to 
a loss of ability to bind microtubules (Iqbal et al. J Neurol 
591213-222 (2000). 
Senile plaques are extracellular deposits composed of a 
central core of amyloid [3 peptide (A6), a 40 or 42 amino acid 
polypeptide derived from the amyloid precursor protein 
(APP). Surrounding the amyloid core are dystrophic neurites 
and reactive glia. Formation of AB occurs through combined 
action of beta and gamma secretase cleavage of APP leading 
to the neurotoxic A[340/42. Mutations inAPP associated With 
FAD are associated With increased generation of A[340/42. 
Mutations in presenilin-1 and 2 (gamma secretases) are also 
associated With FAD and lead to increased production of 
A[340/ 42 . Although NET and SP are the hallmark neuropatho 
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logic markers of AD, it is unclear if they are involved in the 
etiology of AD or are merely end products of neurodegenera 
tion. Additionally, it has been suggested that AD pathology 
may begin 20 to 30 years before the onset of clinical symp 
toms (Davies et al. Neurology 3811688-93 (1988); Price and 
Morris Ann Neurol 451358-68 (1999)). During the preclinical 
period, NET and SP increase until reaching a critical thresh 
old When clinical symptoms appear. 
Without a clear genetic in?uence on sporadic AD several 
etiologic/pathogenic hypotheses have been suggested includ 
ing energy metabolism defects, de?ciencies of neurotrophic 
factors, glutamate toxicity, mitochondrial defects, trace ele 
ment toxicity and free radical mediated toxicity. 
Clinically, AD is characterized by a loss of spontaneity, 
drive and initiative, a progressive Worsening of memory, 
behavioral changes, onset betWeen 40 and 90, and the absence 
of systemic disorders or other brain diseases. The main clini 
cal feature of AD is a progressive cognitive decline leading to 
memory loss. The memory dysfunction involves impairment 
of learning neW information Which is often characterized as 
short-term memory loss. In the early (mild) and moderate 
stages of the illness, recall of remote Well-leamed material 
may appear to be preserved, but neW information cannot be 
adequately incorporated into memory. Disorientation to time 
is closely related to memory disturbance. 
Language impairments are also a prominent part of AD. 
These are often manifest ?rst as Word ?nding dif?culty in 
spontaneous speech. The language of the AD patient is often 
vague, lacking in speci?cs and may have increased automatic 
phrases and cliches. Di?iculty in naming everyday objects is 
often prominent. Complex de?cits in visual function are 
present in many AD patients, as are other focal cognitive 
de?cits such as apraxia, acalculia and left-right disorienta 
tion. Impairments of judgment and problem solving are fre 
quently seen. 
Non-cognitive or behavioral symptoms are also common 
in AD and may account for an even larger proportion of 
caregiver burden or stress than the cognitive dysfunction. 
Personality changes are commonly reported and range from 
progressive passivity to marked agitation. Patients may 
exhibit changes such as decreased expressions of affection. 
Depressive symptoms are present in up to 40% of AD sub 
jects. A similar rate for anxiety has also been reported. Psy 
chosis occurs in 25% of AD subjects. In some cases, person 
ality changes may predate cognitive abnormality. 
Currently, clinical diagnosis of AD is based on structured 
intervieWs (patient histories), and neurop sychological exami 
nations coupled With imaging or neurophysiological scans 
(CT, MRI, PET and/or SPECT scans and EEG) to rule out 
other explanations of memory loss including temporary (de 
pression or vitamin B12 de?ciency) or permanent conditions 
(stroke) and is based on NINCDS-ADRDA Work group cri 
teria (McKhann et al. Neurology 341939-48 (1984) and the 
American Psychiatric Association Diagnostic and Statistical 
Manual of Mental Disorders (4th Ed. Washington DC, Am 
Psychiatric Assoc. (1997). 
Unfortunately, clinical diagnostic methods are not fool 
proof. Evidence based revieW of current literature shoWs 
clinical diagnostic accuracy of 65 to 90%. Higher accuracy 
rates are generally associated With specialized centers 
(memory disorder clinics) focused on memory disorders 
Whereas loWer rates are likely associated With primary care 
physicians. Additionally, accuracy of the clinical diagnosis is 
likely loWer during early stages of the disease When symp 
toms are dif?cult to differentiate from normal age-associated 
cognitive decline. More recently, studies suggest that a con 
dition termed mild cognitive impairment (MCI) represents 
US 7,851,172 B2 
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prodromal AD and if diagnosed early represents the best 
opportunity for pharmaceutical intervention. The clinical cri 
teria used for diagnosis of MCI are those of Petersen et al. 
(Arch Neurol 56:303-308 (1999) and include: 1) memory 
complaints corroborated by an informant, 2) objective 
memory impairment for age and education, 3) normal general 
cognitive function, 4) intact activities of daily living, and 5) 
the subject does not meet criteria for dementia. 
Further complicating diagnosis and treatment of AD is the 
lack of a reliable biomarker that speci?cally identi?es AD 
subjects, particularly early in the prodromal stage of the dis 
ease (MCI). 
In vieW of the magnitude of the public health problem 
posed by AD, considerable research efforts have been under 
taken to elucidate the etiology of AD as Well as to identify 
biomarkers, characteristic proteins or metabolites objectively 
measured as an indicator of pathogenic processes, that can be 
used to diagnose and/ or predict Whether a person is likely to 
develop AD. 
Most studies of biomarkers of AD have focused on mea 
surement in the cerebrospinal ?uid (CSF). CSF is produced in 
the choroid plexus, a leaf like structure that projects into the 
lateral, third and fourth ventricles of the brain (Huhmer et al. 
Disease Markers 22:3-26 (2006)) and is in direct contact With 
the extracellular space of the brain. Because of its intimate 
contact With the brain, pathogenic changes in the brain that 
result in alterations in proteins/peptides Would likely be 
re?ected in the CSF. 
A number of US. patents and published applications relate 
to methods for diagnosing AD, including US. Pat. Nos. 
4,728,605, 5,874,312, 6,027,896, 6,114,133, 6,130,048, 
6,210,895, 6,358,681, 6,451,547, 6,461,831, 6,465,195, 
6,475,161, 6,495,335, 2005/0244890, and 2005/0221348. 
Additionally, a number of reports in the scienti?c literature 
relate to certain biochemical markers and their correlation/ 
association With AD, including Fahnestock et al., 2002, J. 
Neural. Transm. Suppl. 2002(62):241-52; Masliah et al., 
1195, Neurobiol. Aging 16(4):549-56; PoWer et al., 2001, 
Dement. Geriatr. Co gn. Disord. 12(2): 1 67-70; and Burbach et 
al., 2004, J. Neurosci. 24(10):2421-30. Additionally, Li et al. 
(2002, Neuroscience 113(3):607-15) and Sanna et al. (2003, 
J. Clin. Invest. 111(2):241-50) have investigated Leptin in 
relation to memory and multiple sclerosis, respectively. 
Three different biomarkers in CSF have been particularly 
Well documented: neuronal thread protein, tau (total; T-tau 
and various phosphorylated forms; P-tau) and derivatives of 
amyloid precursor protein (APP) including A640 and A642. 
Neuronal thread protein is described to be overexpressed in 
brain neurons in AD patients. A quantitative test for measur 
ing levels of a speci?c type of neuronal thread protein (AD7c 
NTP) in CSF and urine has been developed. Quite a number 
of studies have evaluated CSF-tau as an ante-mortem marker 
for AD mainly using enZyme-linked immunoabsorbent 
assays (ELISA) as the measurement assay. In past studies, 
total tau (T-tau) has been measured although there is an 
increasing body of literature also describing the analysis of 
phosphorylated (P-tau) variants of the same protein involved 
in the formation of NFTs. ELISAs that can distinguish 
betWeen the major form ofA[3 ending at amino acid 40 (A640) 
and the senile plaque forming species ending at position 42 
(A642) have also been developed and evaluated extensively 
for CSF analysis. These three assays, either used individually, 
or in the case of tau and AB 42, in combination, have not 
demonstrated the required sensitivity and speci?city values 
for routine clinical use, particularly for early diagnosis and 
discrimination betWeen AD and other non-AD dementias. In 
addition, attempts to measure tau andA[342 in blood have been 
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met With limited success, further restricting their Widespread 
adoption into clinical practice. 
A Wide spectrum of other aberrations, other than NTP, Tau 
and AB, has been reported in AD patient CSF. Many of the 
identi?ed (protein sequence con?rmed) CSF markers 
reported herein have been shoWn to be either increased or 
decreased in AD patients versus normal individuals. For 
example, the protein Ubiquitin is knoWn to complex With 
hyperphosphorylated Tau during maturation of NFTs in the 
brains of AD patients (Iqbal et. al. J Neural Transm Suppl. 
53:169-80 (1998)). Ubiquitin levels in CSF ofAD and neu 
rological control groups have been shoWn to be signi?cantly 
higher than those of non-neurological aged controls (Wang et. 
al. Acta Neuropathol (Berl). 82(1):6-12 (1991); Kudo et. al. 
Brain Res. 639(1):1-7 (1994)). 
The acute phase/in?ammatory protein alpha(1)-antichy 
motrypsin (ACT) is overproduced in the AD brain. ACT also 
can promote the formation of, and is associated With, neuro 
toxic amyloid deposits (Potter et. al. Neurobiol Aging. 22(6): 
923-30 (2001)). The levels ofACT in both serum and CSF are 
signi?cantly and speci?cally higher in patients With AlZhe 
imer-type dementia than in control subjects (Matsubara et. al. 
AnnNeurol. 28(4):561-7(1990)). There is a particularly close 
association of increases in CSF-ACT With late onset AD 
(Harigaya et. al. Intern Med. 34(6):481-4 (1995)). 
ChromograninA (CrA) is the major protein of large dense 
core synaptic vesicles and may be of value as a biochemical 
marker for synaptic function in AD. One report described no 
difference betWeen AD, vascular dementia, and age-matched 
control groups except When comparing a familial subtype 
(AD Type I) With controls Where there Was a statistically 
signi?cant elevation of CSF CrA in the diseased individuals 
(BlennoW et. al. Dementia. 6(6):306-11 (1995)). 
Beta-2-Microglobulin ([32M) is an initiator of in?amma 
tory responses modulated by interferons and certain cytok 
ines (Hoekman et.al. Neth. J. Med. 28:551-557 (1985)). A 
proteome analysis of CSF by tWo-dimensional electrophore 
sis (2D-gel) has shoWn a signi?cant increase of [32M in AD 
patients (Davidsson et al., Neuroreport, 13:611-615 (2002)), 
and more recently these results Were con?rmed by SELDI 
analysis (Carrette, O. et. al., Proteomics, 3:1486-1494 
(2003)). 
Transthyretin (TTR) has been shoWn to interact with A6, 
possibly preventing amyloid formation in biological ?uids 
and in the brain. (TsuZuki et al., Neurosci Lett, 10:171-174 
(2000)). One identi?ed TTR isoforrn Was shoWn to be 
increased inAD-CSF using 2D gel analysis of a small number 
ofAD and control patients (Davidsson, supra.). HoWever, this 
result con?icts With other reports shoWing a clear decrease of 
TTR in CSF from AD patients compared With controls (Serot 
et. al. J Neurol Neurosurg Psychiatry. 63(4):506-8 (1997); 
Riisoen et. al. Acta Neurol Scand. 78(6):455-9 (1998)). This 
decrease is also negatively correlated With the senile plaque 
(SP) abundance (Merched et. al. FEBS Lett. 425(2):225-8 
(1 998)). 
Cystatin C, a cysteine protease inhibitor, has been impli 
cated in the neurodegenerative and repair processes of the 
nervous system, and the deposition of the same protein 
together With beta amyloid peptide Was found as cerebral 
amyloid angiopathy (CAA) in different types of dementias 
(Levy et.al. J. Neuropathol. Exp. Neurol. 60:94-104). Full 
length Cystatin C Was found as a CSF marker for AD in a 
previous SELDI pro?ling study (Carrette, supra.). A relative 
blood-brain barrier (BBB) dysfunction is associated With AD 
among very elderly individuals. The CSF/ serum albumin 
ratio can be used as a measure of BBB function. Mean CSF/ 
serum albumin ratio has been reported to be higher in all 
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dementias studied, including AD, than in nondemented indi 
viduals (Skoog et al, Neurology. 50:966-71 (1998)). 
Transferrin (TF) plays a role in anti-oxidant defense in 
serum and is also produced in the brain Where its role in 
oxidative stress is unclear. A study on DoWn’s syndrome 
patients suffering from progressive dementia shoWed 
decreased levels of TF When compared to age-matched con 
trols With no neurological disease (Elovaara Acta Neurol 
Scand. 69(5):302-5(1994)). 
Prostaglandin-D-Synthase (PDS) functions to convert 
prostaglandin H2 to prostaglandin D2 and has been identi?ed 
in several studies of CSF (Harrington et al. Appl Theoret 
Electrophor 3:229-34 (1993); Hiraoka et al. J ChormatogrA 
802:143-48 (1998); Kiraoka et al. Electorphorsis 22:3433 
3437 (2001); KaWashima Mod. Pathol 14:197-201 (2001); 
Mase et al. Neurosci Lett 270:188-190; Mase Neurosci Res 
47:455-459 (2003); Melegos et al. Prostaglandins 54:463 
474 (1997)). Additionally, PDS demonstrates altered iso 
forms in neurologic disorders including AD and Parkinson’ s 
disease. 
The present inventors have addressed the above-identi?ed 
needs by identifying a protein-protein complex that is present 
in AD and MCI CSF and not age-matched control subjects. 
Additionally, the present inventors have invented a diagnostic 
test based on the detection of the protein-protein complex that 
identi?es AD and MCI subjects With a high degree of speci 
?city. Levels of these protein-protein complexes can serve as 
biomarkers to preferentially identify subjects With AD from 
age-matched control subjects or subjects With other neuro 
logic disorders. In addition, these biomarker complexes can 
be used to identify subjects With mild cognitive impairment 
(MCI), the earliest clinical manifestation of AD. 
The diagnostic test of the present invention is of consider 
able interest and bene?t because of its ability to identify 
subjects With AD, particularly early in the progression of the 
disease (MCI). The tests of the present invention may also be 
used to monitor e?icacy of treatment. 
SUMMARY OF THE INVENTION 
As indicated herein, an embodiment of the present inven 
tion provides a method for the diagnosis of MCI and AD or 
methods of aiding in the diagnosis of neurological disorders, 
including AD, by quantifying the amount of a protein-protein 
complex-based biomarker in a biological ?uid sample of the 
subject, such as a cerebrospinal ?uid, and comparing the 
measured amount With a reference value for the biomarker. 
The information thus obtained may be used to aid in the 
diagnosis, or to diagnose the disease in the individual. The 
protein complex-based biomarkers are differentially present 
in subjects having a neurological disease, including AD, ver 
sus subjects free of the disease, or subjects having a different 
form of dementia. 
One embodiment of the present invention is a method of 
diagnosing or assessing the likelihood that a patient is 
a?llicted With a neurological disease, including AD, the 
method comprising measuring a level of a protein complex 
biomarker of the present invention. 
Another embodiment of the present invention is a method 
comprising monitoring the progression of a neurodegenera 
tive disease, including AD, comprising measuring a level of a 
protein complex biomarker of the present invention. 
Another embodiment of the present invention comprises 
monitoring the e?icacy of a treatment method of a neurode 
generative disease, including AD, comprising measuring a 
level of a protein complex biomarker of the present invention. 
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Another embodiment of the present invention comprises 
qualifying a neurodegenerative disease, including AD, in a 
subject, comprising measuring a level of a protein complex 
biomarker of the present invention. 
In the above and other embodiments of the present inven 
tion, the measured level of the biomarker is correlated With 
neurological disease. In embodiments, this may be accom 
plished by comparing the measured amount to a reference 
value for the biomarker. The reference value can be obtained 
by measuring an amount of the biomarker in age-matched 
control subjects that are not affected by the disease, or that are 
free of the disease. 
Another embodiment of the present invention comprises 
monitoring the e?icacy of a treatment method of a neurode 
generative disease, including AD, comprising measuring a 
level of a protein complex biomarker of the present invention. 
In embodiments, the e?icacy of treatment is measured by 
monitoring levels of the biomarker in the subject compared to 
a reference, and/or compared to other previous tests of the 
subject. 
In embodiments of the present invention, the biomarker of 
the present invention includes a complex comprised of a 
transthyretin molecule and a prostaglandin-H2 D-isomerase 
molecule. 
Accordingly, one aspect of the present invention is a 
method of aiding diagnosis, or diagnosing a neurological 
disorder, comprising comparing a measured level of a biom 
arker that comprises transthyretin and prostaglandin-H2 
D-isomerase in a biological ?uid sample from an individual to 
a reference level for the biomarker. 
In other aspects, the above method further comprises the 
step of managing the individual treatment based on the status. 
For example, if measurement of the biomarker correlates With 
the presence of AlZheimer’s disease, then managing treat 
ment comprises administering a drug to sloW the progression 
of the disease. Further measurements can be compared to the 
previous measurements, or the standard to monitor the pro 
gression of the disease. 
In a further aspect of the invention, the method further 
comprises measuring the biomarker after treatment has 
begun, to monitor the progression of the disease. 
In still another aspect, the present invention provides a kit 
comprising a solid support comprising at least one capture 
reagent attached thereto, Wherein the capture agent binds one 
component of the biomarker protein complex of the present 
invention. The kit also contains a second reagent to interact 
With the second portion of the trapped complex and reagents 
to measure levels of the second protein. 
Other features, objects, and advantages of the invention 
and its various embodiments Will become apparent from the 
instant disclosure, including the detailed description, 
examples, and claims. 
BRIEF DESCRIPTIONS OF THE DRAWINGS 
FIG. 1 is a graph shoWing levels of the protein complex 
biomarker measured as ng/ml complexed transthyretin in 
ventricular CSF from subjects With non-AD neuropatholo 
gies, MCI, EAD, LAD and age-matched control subjects. 
FIG. 2 is a graph shoWing a statistically signi?cant positive 
correlation exists betWeen levels of complexed transthyretin 
as a measure of the protein complex and Braak staging scores, 
a measure of NET pathology (higher Braak scoreimore 
severe pathology). 
FIG. 3 is a graph shoWing individual concentrations of the 
protein complex biomarker measured as ng/ml complexed 
transthyretin in CSF samples from living probable AD and 
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age-matched control subjects. All control subjects (N:13) 
except for 1 showed levels of the protein complex beloW the 
minimum detection limit (mean:SEM:3.6:0.7 ng/ml). 
FIG. 4 is a graph showing meanzSEM levels of the biom 
arker protein complex measured as ng/ml complexed tran 
sthyretin in lumbar CSF from living probable AD and age 
matched control subjects. 
FIG. 5 is a graph shoWing levels of the protein complex 
signi?cantly negatively correlate With mini mental status 
examination (MMSE) scores (loWer MMSE4diminished 
cognitive function). 
FIG. 6 is a diagram shoWing a sandWich ELISA protocol of 
the present invention. 
DESCRIPTION OF THE INVENTION 
In embodiments of the present invention, the protein com 
plexes of the preset invention are markers for neurodegenera 
tive diseases, including mild cognitive impairment and 
AlZheimer’s disease. Levels of the protein complex of the 
present invention are elevated in bodily ?uids, including cere 
brospinal ?uid, as compared to normal, non-demented age 
and gender-matched controls and comparatively demented 
patients. Thus, the biomarkers of the present invention can be 
used to classify a subject sample as having MCI, AlZheimer’s, 
or normal. 
DEFINITIONS 
As used herein, the terms “AlZheimer’s patient”, “AD 
patient”, and “individual diagnosed With AD” all refer to an 
individual Who has been diagnosed WithAD or has been given 
a probable diagnosis of AlZheimer’s Disease (AD). 
When used herein, methods for “aiding diagnosis” refer to 
methods that assist in making a clinical determination regard 
ing the presence, or nature, of the AD or MCI, and may or may 
not be conclusive With respect to the de?nitive diagnosis. 
Accordingly, for example, a method of aiding diagnosis of 
AD can comprise measuring the amount of one or more AD 
biomarkers in a biological sample from an individual. 
When used herein, the term “predicting” refers to making 
a ?nding that an individual has a signi?cantly enhanced prob 
ability of developing a certain neurological disease. 
As used herein, the phrase “neurological disease” refers to 
a disease or disorder of the central nervous system. Neuro 
logical diseases include multiple sclerosis, neuropathies, and 
neurodegenerative disorders such as AD, Parkinson’s dis 
ease, amyotrophic lateral sclerosis (ALS), mild cognitive 
impairment (MCI) and frontotemporal dementia. 
As used herein, “biological ?uid sample” encompasses a 
variety of ?uid sample types obtained from an individual and 
can be used in a diagnostic or monitoring assay. The de?nition 
encompasses Whole blood, blood serum or blood plasma, 
cerebrospinal ?uid (CSF), urine and other liquid samples of 
biological origin. The de?nition also includes samples that 
have been manipulated in any Way after their procurement, 
such as by treatment With reagents, solubiliZation, or enrich 
ment for certain components, such as proteins or polynucle 
otides. 
An “individual” is a mammal, more preferably a human. 
Mammals include, but are not limited to, humans, primates, 
farm animals, sport animals, rodents and pets. 
A “Normal” individual or sample from a “Normal” indi 
vidual as used herein for quantitative and qualitative data 
refers to an individual Who has or Would be assessed by a 
physician as not having AD or MCI, and has an Mini-Mental 
State Examination (MMSE) (referenced in Folstein et al., J. 
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Psychiatr. Res 1975; 12:1289-198) score or Would achieve a 
MMSE score in the range of 25-30. A “Normal” individual is 
generally age-matched Within a range of 5 to 10 years, includ 
ing but not limited to an individual that is age-matched, With 
the individual to be assessed. 
An individual With “mild cognitive impairment” is an indi 
vidual Who meets the folloWing clinical criteria of amnestic 
MCI (Petersen et al. Arch Neurol 56:303-308 (1999): 1) 
memory complaints corroborated by an informant, 2) objec 
tive memory impairment for age and education, 3) normal 
general cognitive function, 4) intact activities of daily living, 
and 5) the subject does not meet criteria for dementia. 
An “individual With moderate (early) AD (EAD)” is an 
individual Who demonstrate the folloWing criteria: 1) a 
decline in cognitive function for a previous higher level, 2) 
declines in one or more areas of cognition in addition to 
memory, 3) a clinical dementia rating scale score of 0.5 to 1, 
and 4) a clinical examination that excluded other causes of 
dementia. 
An “individual With severe (late stage) AD (LAD)” is an 
individual Who meets the standard clinical diagnostic criteria 
for probable AD (McKhann et al. Neurology 34:939-48 
(1 984). 
As used herein, the term “treatment” refers to the allevia 
tion, amelioration, and/or stabiliZation of symptoms, as Well 
as delay in progression of symptoms of a particular disorder. 
For example, “treatment” of AD includes any one or more of: 
elimination of one or more symptoms of AD, reduction of one 
or more symptoms of AD, stabiliZation of the symptoms of 
AD (e. g., failure to progress to more advanced stages of AD), 
and delay in progression (i.e., Worsening) of one or more 
symptoms of AD. 
As used herein, a “reference value” can be an absolute 
value; a relative value; a value that has an upper and/ or loWer 
limit; a range of values; an average value; a median value, a 
mean value, or a value as compared to a particular control or 
baseline value. A reference value can be based on an indi 
vidual sample value, such as for example, a value obtained 
from a sample from the individual WithAD, MCI or cognitive 
impairment, but at an earlier point in time, or a value obtained 
from a sample from an AD patient other than the individual 
being tested, or a “normal” individual, that is an individual not 
diagnosed With AD. The reference value can be based on a 
large number of samples, such as from AD patients or normal 
individuals or based on a pool of samples including or exclud 
ing the sample to be tested. 
As used herein, a , an”, and “the” can mean singular or 
plural (i.e., can mean one or more) unless indicated other 
Wise. 
As indicated herein, the present invention involves biom 
arkers. A biomarker is a characteristic biomolecule Which is 
differentially present in a sample taken from a subject of one 
phenotypic status (e.g., having a disease) as compared With 
another phenotypic status (e.g., not having the disease). A 
biomarker is differentially present betWeen different pheno 
typic statuses if the mean or median expression level of the 
biomarker in the different groups is calculated to be statisti 
cally signi?cant. Biomarkers, alone or in combination, pro 
vide measures of relative risk that a subject belongs to one 
phenotypic status or another. Therefore, they are useful as 
markers for disease (diagnostics), therapeutic effectiveness 
of a drug (theranostics) and drug toxicity. 
In this invention, novel biomarkers are discussed that are 
differentially present in subjects having neurodegenerative 
diseases such as AD versus subjects free of the disease. In 
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addition, the present invention provides methods of using the 
protein complex-based biomarkers to qualify AlZheimer’s 
disease in a subject. 
The biomarker complex Was discovered using molecular 
Weight fractionation to isolate proteins betWeen about 50 and 
100 kDa, 2-dimensional electrophoresis and MALDI mass 
spectrometry for protein identi?cation. Protein identi?cation 
Was based on database searches using SEQUESTTM. Based 
on initial studies of proteins isolatedbetWeen 50 and 100 kDa, 
several proteins of molecular Weight less than 50 kDa Were 
identi?ed. Using l-dimenstional electrophoresis and Western 
blot analysis, a band of ~55 kDa Was identi?ed that Was 
immunopositive for both prostaglandin-d-synthase and tran 
sthyretin suggesting a protein complex or aggregate. Based 
on these observations, an embodiment of the present inven 
tion, an enzyme linked immunoassay (ELISA) Was devel 
oped that traps prostaglandin-D-synthase and probes for and 
quanti?es attached transthyretin. 
More speci?cally, to interrogate CSF for novel biomarker 
proteins, the present inventors subjected ventricular CSF 
obtained at autopsy from late stage AD (LAD) and age 
matched control subjects to molecular Weight (MW) fraction 
ation and 2-dimensional electrophoresis. Mass spectrometry 
of these molecular Weight fractions shoWed the presence of a 
series of proteins in MW fractions higher than expected 
Which among other scenarios, suggested that these proteins 
may be part of an aggregate or complex. 
Using this approach, the present inventors identi?ed dif 
ferentially expressed proteins in LAD CSF, including beta-2 
microglobulin, carbonic anhydrase, cystatin C, copper/Zinc 
superoxide dismutase (Cu/Zn SOD), phosphytidylethanola 
mine binding protein, plasma retinol binding protein, pros 
taglandin-d-synthase (PDS), serotransferrin and transthyretin 
(TTR). Under normal conditions, most of the observed dif 
ferentially expressed proteins except serotransferrin and 
homotetrameric TTR Would be expected to be in the less than 
about 50 kDa fraction. Western blot analysis of fractionated 
CSF samples shoWed a band of ~55 kDa that Was immunopo 
sitive for Cu/Zn SOD, TTR and PDS. In addition to the higher 
molecular Weight band, bands corresponding to the native 
monomeric proteins Were also observed using each antibody 
suggesting loss of native protein from the complex folloWing 
addition of denaturing gel loading buffer. 
Comparison of levels of native monomeric proteins 
shoWed no signi?cant differences betWeen LAD and control 
subjects for PDS or Cu/Zn SOD. Levels of monomeric TTR 
(MW ~16 kDa) shoWed a signi?cant elevation in LAD CSF 
although there Was considerable overlap of individual subject 
values betWeen the tWo populations, limiting the usefulness 
of the native proteins as a diagnostic biomarker. In contrast, 
levels of the ~55 kDa band immunopositive for PDS and TTR 
shoWed signi?cant differences betWeen LAD and control 
subjects With minimal overlap betWeen the 2 populations. 
Calculation of the product of staining intensity using anti 
TTR and anti-PDS shoWed about a 10 fold increase in LAD 
compared to age-matched controls With virtually no overlap 
betWeen the populations. Additionally, analysis of ventricular 
CSF specimens from MCI, early AD (EAD) and LAD sub 
jects shoWed the complex Was signi?cantly elevated in MCI 
subjects and that levels increased in a disease-progression 
related manner. 
To determine if the protein-protein complex is present in 
lumbar CSF, a small number of samples from living, probable 
AD and age-matched control subjects Was analyZed and 
shoWed similar trends With signi?cant elevations in probable 
AD CSF compared to controls. Based on identi?cation of 
components of the protein complex, a sandWich enZyme 
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linked immunoassay (ELISA) is utiliZed that traps a ?rst 
component of the complex and probes for a second compo 
nent. For example, in embodiments of the present invention, 
the sandWich ELISA traps a PDS and probes for the second 
component, TTR. 
Preliminary analysis of a small number of ventricular CSF 
specimens from MCI, EAD, LAD and age-matched control 
subjects shoWed the complex Was signi?cantly elevated in 
MCI (122124 ng/ml), EAD (120117 ng/ml) and LAD 
(115120 ng/ml) subjects compared to age-matched controls 
(<5 ng/ml). Additionally, CSF from subjects With other neu 
rologic disorders including Parkinson’s disease (PD), diffuse 
LeWy body disease (DLB), progressive supranuclear palsy 
(PSP) and frontotemporal dementia (FTD) shoWed concen 
trations <5 ng/ml, suggesting a high degree of sensitivity/ 
speci?city for the diagnosis of AD. Preliminary analysis of 
lumbar CSF specimens from a small number of living, prob 
able AD and age-matched controls shoWed that the protein 
complex is present in probable AD subjects (about 37.5162 
ng/ml) and that it is about 100% sensitive and about 93% 
speci?c in the identi?cation of AD subjects compared to 
age-matched controls (about <5 ng/ ml) With minimal overlap 
betWeen the subject populations. 
Such data suggest that levels of a unique protein complex 
consisting of embodiments of the present invention, includ 
ing TTR and PDS, may serve as a sensitive and speci?c 
diagnostic biomarker of AD and more importantly appears to 
identify subjects With MCI. 
Reference Levels 
The reference level used for comparison With the measured 
level for a AD biomarker may vary, depending on aspect of 
the invention being practiced, as Will be understood by one of 
ordinary skill in the art. For AD diagnosis methods, the “ref 
erence level” is typically a predetermined reference level, 
such as an average of levels obtained from a population that is 
not a?llicted With AD or MCI, but in some instances, the 
reference level can be a mean or median level from a group of 
individuals including AD patients. In some instances, the 
predetermined reference level is derived from (e.g., is the 
mean or median of) levels obtained from an age-matched 
population. 
For MCI diagnosis methods (i.e., methods of diagnosing or 
aiding in the diagnosis of MCI), the reference level is typi 
cally a predetermined reference level, such as an average of 
levels obtained from a population that is not a?llicted WithAD 
or MCI, but in some instances, the reference level can be a 
mean or median level from a group of individuals including 
MCI and/or AD patients. In some instances, the predeter 
mined reference level is derived from (e.g., is the mean or 
median of) levels obtained from an age-matched population. 
For AD monitoring methods (e.g., methods of diagnosing 
or aiding in the diagnosis of AD progression in an AD 
patient), the reference level may be a predetermined level, 
such as an average of levels obtained from a population that is 
not a?llicted With AD or MCI, a population that has been 
diagnosed With MCI or AD, and, in some instances, the ref 
erence level can be a mean or median level from a group of 
individuals including MCI and/or AD patients. Alternately, 
the reference level may be a historical reference level for the 
particular patient (e.g., a level that Was obtained from a 
sample derived from the same individual, but at an earlier 
point in time). In some instances, the predetermined reference 
level is derived from (e.g., is the mean or median of) levels 
obtained from an age-matched population. 
For AD strati?cation methods (i.e., methods of stratifying 
AD patients into mild, moderate and severe stages ofAD), the 
reference level is normally a predetermined reference level 
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that is the mean or median of levels from a population Which 
has been diagnosed With AD or MCI (preferably a population 
diagnosed With AD) In some instances, the predetermined 
reference level is derived from (e. g., is the mean or median of) 
levels obtained from an age-matched population. 
Age-matched populations (from Which reference values 
may be obtained) are ideally the same age as the individual 
being tested, but approximately age-matched populations are 
also acceptable. Approximately age-matched populations 
may be Within 1, 2, 3, 4, or 5 years of the age of the individual 
tested, or may be groups of different ages Which encompass 
the age of the individual being tested. Approximately age 
matched populations may be in 2, 3, 4, 5, 6, 7, 8, 9, or 10 year 
increments (eg a “5 year increment” group Which serves as 
the source for reference values for a 62 year old individual 
might include 58-62 year old individuals, 59-63 year old 
individuals, 60-64 year old individuals, 61-65 year old indi 
viduals, or 62-66 year old individuals). 
Comparing Levels of AD Biomarkers 
The process of comparing a measured value and a refer 
ence value can be carried out in any convenient manner 
appropriate to the type of measured value and reference value 
for the AD biomarker at issue. For example, ‘measuring’ can 
be performed using quantitative or qualitative measurement 
techniques, and the mode of comparing a measured value and 
a reference value can vary depending on the measurement 
technology employed. The example, the measured values 
used in the methods of the invention Will most commonly be 
quantitative values (e.g., quantitative measurements of con 
centration, such as nanograms of AD biomarker per milliliter 
of sample, or absolute amount). As With qualitative measure 
ments, the comparison can be made by inspecting the numeri 
cal data, by inspecting representations of the data (e.g., 
inspecting graphical representations such as bar or line 
graphs). 
As an example, a measured value is generally considered to 
be substantially equal to or greater than a reference value if it 
is at least about 95% of the value of the reference value (e.g., 
a measured value of 1.71 can be considered substantially 
equal to a reference value of 1.80). A measured value is 
considered less than a reference value if the measured value is 
less than 95% of the reference value (e. g., a measured value of 
1.7 can be considered less than a reference value of 1.80). 
One embodiment of the present invention is a method for 
quantifying a neurodegenerative disorder in a patient that 
comprises obtaining a ?uid sample from the subject, and 
measuring a protein biomarker complex in said ?uid sample. 
In embodiments of the present invention, the biomarker com 
prises at least one of transthyretin and/or prostaglandin-H2 
D-isomerase, and at least one second protein selected from 
transthyretin, prostaglandin-H2 D-isomerase, beta-2-micro 
globulin, cystatin C, superoxide dismutase [CuiZn], plasma 
retinol-binding protein, phosphatidylethanolamine-binding 
protein, carbonic anhydrase 2, prostaglandin-H2 
D-isomerase, and/or serotransferrin. Mild cognitive impair 
ment or AlZheimer’s disease status is determined by correlat 
ing the obtained measurement With standards. 
In a preferred embodiment of the present invention, the 
protein biomarker complex comprises transthyretin and pros 
taglandin-H2 D-isomerase. 
In another embodiment of the present invention, the mea 
suring step comprises trapping by enZyme linked immun 
osorbent assay (ELISA) at least one of transthyretin and/or 
prostaglandin-H2 D-isomerase; and probing for a second, 
different protein selected from the group consisting of at least 
one of transthyretin, prostaglandin-H2 D-isomerase, beta-2 
microglobulin, cystatin C, superoxide dismutase [CuiZn], 
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plasma retinol-binding protein, phosphatidylethanolamine 
binding protein, carbonic anhydrase 2, prostaglandin-H2 
D-isomerase, and/or serotransferrin is identi?ed by probing 
the trapped protein. 
In the correlating step, the amount of said protein biomar 
ker complex With a reference value in a control sample can be 
compared. In embodiments, the control sample is from a 
normal individual. The control sample can be compared With 
a previous sample taken from a patient. Additionally, the 
method can comprise comparing the control sample With the 
?uid sample of the subject to determine the progression of the 
mild cognitive impairment or the AlZheimer’s disease. 
Preferably, the sample is cerebro spinal ?uid, Which can be 
collected via a spinal tap. 
In one aspect of the present invention, the process may be 
used as a method of monitoring the progression of a neuro 
logical disorder. In this aspect, a ?rst measured level of a 
biomarker complex of the present invention is compared With 
a reference level of the biomarker complex, and after alloWing 
a period of time to pass, comparing a second measured level 
of the biomarker complex to said reference level and/or to 
said ?rst measured level of the biomarker complex. FolloW 
ing this comparison, the progression of the disease based on 
the ?rst and second measured level of said biomarker com 
plex can be determined. 
Another aspect of the present invention is a diagnostic kit 
for quantifying AlZheimer’s disease status. The kit may com 
prise a solid support coated With an antibody to capture at 
lease one of a protein complex selected from prostaglandin 
D-synthase and/or transthyretin; and a second primary anti 
body to recognize the second component of the protein com 
plex, the second component selected from a transthyretin, 
prostaglandin-H2 D-isomerase, beta-2-microglobulin, cysta 
tin C, superoxide dismutase [CuiZn], plasma retinol-bind 
ing protein, phosphatidylethanolamine-binding protein, car 
bonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or 
serotransferrin protein. 
In embodiments, the solid support is a 96 Well polystyrene 
microtiter plate. In others, the solid support is coated With 
anti-prostaglandin-D-synthase for protein capture. 
In embodiments, the second primary antibody recogniZes 
the second component of the protein complex (i.e., rabbit 
anti-human transthyretin), and a horseradish peroxidase con 
jugated secondary antibody against the species used to gen 
erate the second primary antibody (ie goat anti-rabbit), TMB 
color reagent and stopping solutions. 
With respect to embodiments of the present invention, FIG. 
1 shoWs an embodiment of the present invention Where analy 
sis of ventricular CSF from autopsy-con?rmed MCI (N:5), 
EAD (N:4), late stage AD (N:9) and age-matched control 
subjects (N:8) shoWs that presence of the protein complex 
measured as ng/ml Transthyretin identi?es MCI and AD sub 
jects With a high degree of speci?city (100%) and sensitivity 
(AD; 100%; MCI 80%). 
FIG. 2 shoWs a statistically signi?cant positive correlation 
betWeen levels of the protein complex and Braak staging 
scores, a measure of NFT pathology. Analysis of ventricular 
CSF from non-AD pathologies including diffuse LeWy body 
disease (N:5), Parkinson’s disease (N:2), parasupranuclear 
palsy (N :2) and frontotemporal dementia (N:2) shoWs 100% 
speci?city of the biomarker complex for AD and MCI. 
Doubly blinded analysis of lumbar CSF from living AD 
(N :15) and age-matched control subject (N:14) shoWs 100% 
sensitivity and 93% speci?city in identi?cation of AD and 
control subjects (FIG. 3). 
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FIG. 4 shows a statistically signi?cant 10 fold increase in 
levels of the protein complex measured as ng/ ml transthyretin 
in probable AD subjects. 
Additionally there is a statistically signi?cant negative cor 
relation betWeen levels of the protein complex measured as 
ng/ml transthyretin and mini-mental status examination 
(MMSE) scores, a measure of cognitive function (FIG. 5). 
Correlation analysis shoWs there is no statistically signi? 
cant relationship betWeen age and levels of the protein com 
plex. Additionally, there are no sex related differences. 
Use of Modi?ed Forms of a Biomarker 
It has been found that proteins and protein complexes 
frequently exist in a sample in a plurality of different forms 
characterized by differences in phosyphorylation, glycosyla 
tion and oxidative modi?cation including aldehyde modi? 
cation by compounds such as levuglandin, HNE and acrolein. 
Because the antibodies are able to recogniZe the protein 
regardless of posttranslational modi?cations the assay may 
be carried out as described. All the protein and protein com 
plex modi?cations that Would be understood by one of ordi 
nary skill in the art are Within the scope of the present inven 
tion. 
Of course, embodiments of the present invention includes 
various nomenclature forms. For example, cystatin C is also 
knoWn as neuroendocrine basic polypeptide, Gamma-trace, 
Post-gamma-globulin. Transthyretin is also knoWn as preal 
bumin, TBPA, TTR, ATTR. Plasma retinol-binding protein is 
also knoWn as PRBP, RBP. Phosphatidylethanolamine-bind 
ing protein is also knoWn as PEBP, prostatic binding protein, 
HCNPpp, neuropolypeptide h3, Raf kinase inhibitor protein, 
RKIP. Carbonic anhydrase 2 is also knoWn as EC 4.2.1.1, 
Carbonic anhydrase II, Carbonate dehydratase II, CA-II, Car 
bonic anhydrase C. Prostaglandin-H2 D-isomerase is also 
knoWn as EC 5.3.99.2, Lipocalin-type prostaglandin-D syn 
thase, Glutathione-independent PGD synthetase, prostaglan 
din-D2 synthase, PGD2 synthase, PGDS2, PGDS, Beta-trace 
protein, Cerebrin-28. Serotransferrin is also knoWn as trans 
ferrin, siderophilin, beta-1-metal binding globulin. 
Detection of Biomarkers for AlZheimer’s Disease 
The biomarkers of this invention can be detected by any 
suitable method including Western blot analysis and ELISA 
as described herein. ELISA is a preferred technique because 
ofits ease of use. 
Determination of Risk of Developing Disease 
In one embodiment of the present invention is a method for 
determining the risk of pro gressing from amnestic MCI to AD 
in a subject. Biomarker amounts shoW signi?cant positive 
correlations With Braak staging scores that measure the 
degree of neuropathology (speci?cally NET) and signi?cant 
negative correlations With MMSE (mini-mental status exami 
nation scores) that measure cognitive function. Based on the 
concentrations of the protein complex, MCI subjects With 
higher levels Would be projected to advance to AD. 
Data Analysis 
Results of the assay Will be compared statistically using 
analysis of variance to compare disease progression related 
differences. Post hoc testing Will be carried out for pairWise 
comparisons (i.e., control vs. MCI). 
Determining Course (Progression/Remission) of Disease 
In one embodiment, this invention provides methods for 
determining the course of AlZheimer’s disease in a subject. 
Disease course refers to changes in disease status over time, 
including disease progression (Worsening) and disease 
regression (improvement). Over time, the amounts or relative 
amounts (e.g., the pattern) of the biomarkers changes. For 
example, the concentrations of biomarkers Would be 
expected to decrease With appropriate pharmacologic inter 
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ventions. The course of disease may be determined based on 
comparisons. Similarly, this method is useful for determining 
the response to treatment. If a treatment is effective, then the 
biomarkers Will trend toWard normal, While if treatment is 
ineffective, the biomarkers Will trend toWard disease indica 
tions. 
An embodiment of the present invention is methods of 
identifying complexes that can be used as biomarkers of the 
present invention, the biomarkers being useful for diagnosis, 
aiding in diagnosis, stratifying, assessing risk, monitoring 
and/or predicting a neurological disease. Using methods 
described herein, protein spots representing different proteins 
can be identi?ed as signi?cantly different betWeen LAD and 
control subjects. In one example, molecular Weight (MW) 
fractionation of ventricular CSF specimens from 5 LAD and 
5 age-matched controls canbe separated into fractions greater 
than and less than about 50 kDa and subjected to 2-dimen 
sional electrophoresis. Following a comparison of the gels, 
protein spots representing different proteins Were identi?ed 
as signi?cantly different betWeen LAD and control subjects. 
Examples of the proteins identi?ed Were beta-2-microglobu 
lin, cystatin C, Cu/Zn superoxide dismutase, transthyretin, 
plasma retinol-binding protein, phosphatidylethanolamine 
binding protein, carbonic anhydrase 2, prostaglandin-D-syn 
thase, and serotransferrin. The present inventors found that 
the majority of the proteins identi?ed in the greater than 50 
kDa fraction normally Weigh less than 50 kDa and should 
have been isolated in the lighter fraction. Based on this obser 
vation, the present inventors determined the presence of a 
complex. To con?rm that the proteins are present as a com 
plex, CSF samples from 8 LAD and 7 age-matched controls 
are subjected to MW fractionation, freeZe dried, resuspended 
in 30 pl PBS and subjected to Western blot analysis and 
probed for PDS and TTR. Subject demographic data are 
shoWn in Table 1, beloW. 
TABLE 1 
Sub'ect demographic data for ventricular CSF specimens. 
Mean 1 
SEM 
Median complexed 
Mean 1 Mean : Braak TTR 
SEM SEM PMI Staging Fold inc over 
Age (y) Sex (hr) Score control 
Control 83.3 r 2.3 4M/3F 3.4 r 0.4 I 1.0 0.4 
Non-AD 70.4 142* 7M/5F 4.7 r 1.6 II 1.4 0.2 
Neurologic 
Disorders 
MCI 89.8 :1.4* 2M/2F 4.2 r 1.8 IV* 2.9 r 0.5* 
EAD 89.5 r 2.7 1M/3F 2.8 r 0.7 V* 3.7 r 0.3* 
LAD 81.6 r 2.0 4M/4F 3.1 r 0.1 VI* 9.7 r 2.2* 
*p < 0.05 
There Were no signi?cant differences in age or postmortem 
interval (PMI) betWeen LAD and control subjects. Median 
Braak staging scores Were signi?cantly higher in LAD 
(medianIVI) compared to controls (medianII). A use of the 
monoclonal PDS antibody shoWed the presence of native 
PDS (MW:21 kDa) and a strongly immunopositive band at 
~55 kDa that Was more strongly stained inAD specimens than 
in controls. Stripping and reprobing the gels for TTR shoWed 
an immunopositive band corresponding to native TTR 
(MW:16 kDa) and the band at ~55 kDa. To verify speci?city 
of the antibodies, representative LAD CSF specimens Were 
subjected to Western blot analysis using antibodies that had 
been pretreated With representative immuniZing proteins. 
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To determine if the protein complex is present at early 
stages of AD and is speci?c for AD, the present inventors 
carried out Western blot analyses of ventricular CSF samples 
from 4 subjects With MCI, 4 EAD subjects and 12 subjects 
With non-AD neurologic diseases including PD (N:2), PSP 
(N:2), DLB (N:5), and FTD (N:3). Table 1 shoWs subject 
demographic data. There Were no signi?cant differences in 
age betWeen controls, LAD or EAD subjects. MCI subjects 
Were signi?cantly older than control subjects and subjects 
With non-AD pathologies Were signi?cantly younger than 
controls. Median Braak staging scores Were signi?cantly 
higher in MCI (medianIIV), EAD (medianIV) and LAD 
(medianIVI) subjects compared With controls (medianII). 
There Were no signi?cant differences in post mortem inter 
vals for any of the subjects. Measurement of staining intensity 
of the individual native proteins shoWed no signi?cant differ 
ences betWeen LAD and control subjects for TTR although 
PDS Was signi?cantly elevated in LAD CSF. HoWever, there 
Was considerable overlap of individual subjects from the tWo 
populations suggesting limited use of the native proteins as 
biomarkers. Staining intensity of the 55 kDa band Was calcu 
lated as % of control staining for each gel for each of the 
antibodies. Because We hypothesized the amount of the com 
plex and not the native proteins, is indicative of AD, the 
present inventors calculated the product of the tWo percent 
ages. Table 1 shoWs the meanzSEM product of the % control 
staining intensities for control, non-AD pathologies, MCI, 
EAD and LAD subjects and shoWs a signi?cant disease pro 
gression related increase in the protein complex With statis 
tically signi?cant elevations of the complex in MCI, EAD and 
LAD subjects compared With control subjects. To be an effec 
tive biomarker of AD, the substance being studied in CSF 
must be present in brain. To determine if the protein complex 
is present inAD brain, preliminary studies Were carried out to 
determine if the protein complex could be detected in repre 
sentative specimens of HPG from LAD and control subjects. 
Specimens of HPG (N:4 LAD and 4 control) Were homog 
eniZed in HEPES buffer and subjected to Western blot analy 
SlS. 
Preliminary confocal analyses of sections of HPG immu 
nostained for CNPase, a marker of oligodendrocytes or 
GFAP, a marker of glia concurrently With TTR and PDS shoW 
PDS is primarily associated With CNPase-positive oligoden 
drocytes Whereas TTR is more strongly associated With 
GFAP-positive astrocytes. Comparison of LAD and control 
staining shoWs considerably higher levels of TTR and PDS in 
LAD brain compared to age-matched controls. 
Based on the Western blot analyses, the present inventors 
initiated development of an enZyme linked immunoassay 
(ELISA) based on capture of one component of the complex 
and quanti?cation of another component from small volumes 
of CSF. Using standard techniques for the optimiZation of 
ELISA conditions, a serial dilution matrix analysis Was car 
ried out using antibody concentrations betWeen 0 and 1000 
ng/ml PBS containing 0.05% sodium aZide (PBSN). We 
tested both anti-TTR and anti-PDS as the trap antibody With 
the other as the probe antibody. Based on these studies an 
ELISA Was established in Which 96 Well microtiter plates 
Were coated overnight with mouse anti-PDS raised against 
recombinant human PDS at 1 ug/ml PBSN. The plates Were 
rinsed and blocked for 1 hr using 5% dry milk/15% normal 
goat serum in PBSN and incubated With unprocessed CSF. 
Following 5 Washes of PBSN, levels of TTR present in the 
trapped complex Were quanti?ed using rabbit anti-TTR 
raised against amino acids 1-147 of human TTR (1 ug/ml in 
blocking buffer) and horseradish peroxidase conjugated goat 
anti-rabbit secondary antibody (1:1000 dilution/blocking 
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buffer). Color Was developed using 3,3',5,5'-tetramethylben 
Zidine (TMB) color reagent folloWed by addition of stopping 
solution. Absorbance Was read at 450 nm using a multi-Well 
UV-Vis plate reader. Concentrations of TTR Were quanti?ed 
using a calibration curve of knoWn concentrations of human 
TTR (0 to 500 ng/ml) coated in triplicate on each plate. 
To determine limits of detection (LOD) and mean correla 
tion coef?cients using this approach, replicate analyses of 
standard solutions of TTR Were carried out using 0, 25, 50, 
100, 250 and 500 ng/ml TTR in PBSN (6 Wells/plate; 3 
plates). Calculation of correlation coef?cients shoWed a sta 
tistically signi?cant (p<0.01) positive correlation 
(r:0.92:0.02) betWeen concentration and absorbance sug 
gesting a good linearity of response over a Wide concentration 
range. Calculation of mean LOD shoWed a meanzSEM value 
of3.6:0.7 ng/ml. 
To verify the ELISA described above provides similar 
results to those observed using Western blot anlaysis, aliquots 
of unprocessed ventricular CSF from subjects Were subjected 
to the ELISA in triplicate. Table 2, beloW shoWs results of the 
analyses for individual subjects and shoWs that there is no 
overlap of the subject populations. 
TABLE 2 
Individual complexed TTR concentrations (ng/ml CSF) in ventricular CSF. 
Non-AD 
Control Pathologies MCI EAD LAD 
<5 ng/rnl <5 ngrnl 93.0 175.0 205.0 
<5 ng/rnl <5 ngrnl 110.0 139.5 61.0 
<5 ng/ml <5 ngml 93.0 93.0 27.5 
<5 ng/ml <5 ngml 192.0 74.0 46.5 
<5 ng/ml <5 ngml 74.0 
<5 ng/ml <5 ngml 141.0 
<5 ng/ml <5 ngml 262.5 
<5 ng/ml <5 ngml 
<5 ngml 
<5 ngml 
<5 ngml 
<5 ngml 
<5 ng/ml <5 ngml 122 1 120.0 :17.3* 115.4 1196* 
23.7* 
*p < 0.05 
Control subjects and those With non-AD pathologic disor 
ders shoWed levels beloW detection limits (<5 ng/ml) Whereas 
all MCI, EAD and LAD subjects shoWed values considerably 
higher than the LOD. Comparison of mean values using Stu 
dent’s t-test shoWed concentrations of complexed TTR Were 
signi?cantly elevated in MCI, EAD and LAD CSF compared 
to control subjects (Table 2). As Was observed for Western 
blot analyses, there Were no differences betWeen control and 
non-AD pathologies. Although these data represent a small 
number of subjects, it demonstrates 100% sensitivity and 
100% speci?city for the identi?cation of subjects at all stages 
of AD including MCI. Because a suitable biomarker of AD 
should correlate With some aspect of the neuropathology, 
correlation analyses Were carried out for all subjects compar 
ing Braak staging score, a measure of NET pathology, and 
levels of complexed TTR and shoWed a statistically signi? 
cant (p<0.01) positive correlation (r:+0.66) betWeen levels of 
complexed TTR and Braak score. Based on these data, use of 
a protein complex consisting of TTR and PDS appears to be 
e?icient in the identi?cation ofAD subjects at all stages ofAD 
including MCI in ventricular CSF specimens. 
To be effective as a diagnostic biomarker for AD, the 55 
kDa protein complex identi?ed must be present at a quanti 
?able level in a relatively easily sampled ?uid such as lumbar 
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CSF. To determine if the protein complex is present in lumbar 
CSF, specimens Were obtained from 15 living probable AD 
subjects and 14 age-matched control subjects and Were ana 
lyZed in a doubly blinded fashion using the ELISA described 
above. Table 3, beloW, shoWs subject demographic data. 
There Were no signi?cant differences in age betWeen AD and 
control subjects. Mean MMSE scores Were signi?cantly 
(p<0.05) loWer in AD subjects (19312.4) compared to con 
trols (29210.2). 
TABLE 3 
Subject demographic data for living probable AD and control subjects. 
Mean 1 
Mean 1 SEM Mean : MMSE SEM 
Age (y) Sex Score TTR (ngml) 
Control 71.0 r 1.9 10 M/4 F 29.2 r 0.2 37.5 r 62* 
ProbableAD 68.4 r 1.8 5 M/10 F 19.3 114* 1.9 11.9 
*p < 0.05 
Table 4 shoWs results of the analyses for individual subjects 
and shoWs that 13 of 14 control subjects had complexed TTR 
concentrations beloW the LOD Whereas all 15 probable AD 
subjects had levels higher than the LOD. Mean complexed 
TTR concentrations in AD lumbar CSF (37516.2 ng/ml) 
Were ~1/3 those observed in ventricular CSF (110:5 ng/ml) 
but Were signi?cantly higher than the mean level in control 
subjects (6111.6 ng/ml). The control meanzSEM Was calcu 
lated using 5 ng/ml for LOD values. 
TABLE 4 
Individual complexed TTR concentrations 
for living probable AD and control subjects. 
Control Probable AD 
<5 ng/ml 40.5 
<5 ng/ml 32.5 
<5 ng/ml 50.5 
<5 ng/ml 46 
<5 ng/ml 26 
<5 ng/ml 69.5 
<5 ng/ml 53.5 
<5 ng/ml 24.5 
<5 ng/ml 22.5 
<5 ng/ml 21.0 
<5 ng/ml 26.5 
<5 ng/ml 109.5 
<5 ng/ml 25.5 
26.5 19.5 
6.0 
Mean:SEM=6.1 : 1.6 Mean: SEM=37.5 16.2 
Calculation of sensitivity and speci?city values for this 
relatively small sample siZe shoWed a sensitivity of 100% and 
a speci?city of 93%. Correlation analysis of levels of com 
plexed TTR and MMSE scores shoWed a statistically signi? 
cant (p<0.001) negative correlation (r:—0.68) suggesting lev 
els of the complex increase as cognitive function declines. 
Comparison of concentrations of complexed TTR as a func 
tion of gender shoWed no gender related differences. 
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The folloWing non-limiting examples are presented as 
being exemplary of the present invention, and are not to be 
construed as limiting thereof. 
EXAMPLE 1 
Determining Presence of Biomarker in Sample 
CSF samples Were collected from 6 MCI, 4 EAD, 9 LAD 
and 8 age-matched control subjects at autopsy from the lateral 
ventricle using an 18 gauge cannula attached to virgin 
polypropylene syringes. TWenty to ?fty milliliters of CSF 
Were WithdraWn, centrifuged at 10,000 g to pellet cells and 
aliquoted into 2 ml cryovials. The vials Were immediately 
froZen in liquid nitrogen and maintained at —800 C. until used 
for analysis. For speci?city studies CSF specimens Were 
obtained in a similar manner from 5 subjects With diffuse 
LeWy body disease (LB), 2 subjects With Parkinson’s disease 
(PD), 2 subjects With parasupranuclear palsy (PSP) and 3 
subjects With frontotemporal dementia (FTD). Subjects used 
in these studies met standard histopathologic criteria for the 
diagnosis ofAD (Mirra et al. Neurology 91 :479-484 (1991); 
NIA-Reagan Institute Neurobiol Aging 18:S1-2 (1997). All 
control patients Were folloWed longitudinally at the Univer 
sity of Kentucky AlZheimer’s Disease Center (ADC) Clinic 
and had neurop sychological testing annually Which remained 
in the normal range. All MCI patients Were normal on enroll 
ment into the University of Kentucky’s longitudinal study 
and developed MCI during folloW up. The criteria used for 
clinical diagnosis of amnesic MCI Were those described by 
Petersen (Petersen et al. Arch Neurol 56:303-308 (1999) and 
include: 1) memory complaints corroborated by an infor 
mant, 2) objective memory impairment for age and education, 
3) normal general cognitive function, 4) intact activities of 
daily living, and 5) the subject does not meet criteria for 
dementia. The clinical criteria for EAD Were 1) a decline in 
cognitive function for a previous higher level, 2) declines in 
one or more areas of cognition in addition to memory, 3) a 
clinical dementia rating scale score of 0.5 to 1, and 4) a 
clinical examination that excluded other causes of dementia. 
All subjects had neuropathological evalution of sections of 
neocortex, hippocampus, entorhinal cortex, amygdala, basal 
ganglia, nucleus basalis of Meynert, midbrain, pons, medulla, 
and cerebellum using the modi?ed BielschoWsky stain, 
hemotoxylin-eosin stain, and 10D-5 and alpha synuclein 
immunostains. Braak staging (Braak and Braak Acta Neuro 
pathol 82:239-259 (1991) Was determined using the Gallyas 
stain on sections of entorhinal cortex, hippocampus, and 
amygdala, and the BielschoWsky stain on the neocortex. 
None of the MCI, EAD, LAD, or control subjects demon 
strated signi?cant LeWy body pathology. The distinction 
betWeen MCI and control patients Was a signi?cant increase 
in neuritic plaques in neocortical regions and a signi?cant 
increase in neuro?brillary tangles in entorhinal cortex, hip 
pocampus, and amygdala in MCI patients (Markesbery et al. 
Arch Neurol 63:38-46, 2006). Braak staging scores in control 
subjects Were I to II and met the NIA-Reagan Institute loW 
likelihood for the histopathological diagnosis of AD. The 
Braak staging scores of MCI subjects ranged from III to IV. 
EAD subjects met high likelihood criteria for the histo 
pathogical diagnosis of AD With a Braak staging score of V. 
Braak staging scores in AD subjects Were VI. Subjects With 
non-AD pathologies met standard histopathologic criteria for 
each disease. 
Lumbar CSF samples Were collected from subjects diag 
nosed With probable AlZheimer’s disease (N:15) and sub 
jects diagnosed as normal (non-demented) (N:14) the mom 
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ing after fasting since midnight. The L3-4 or L4-5 interspace 
Was in?ltrated With 1% lidocaine using a 25 gauge needle for 
super?cial and deep anesthesia. Lumbar puncture Was per 
formed With the patient in lateral decubitus or sitting using a 
24 gauge Sprotte bullet tip atraumatic spinal needle and a 20 
gauge spinal introducer. CSF Was WithdraWn using virgin 5 
ml polypropylene syringes. Subjects Were analyZed in a 
blinded fashion and Were either probableAD subjects (N :1 5) 
or age-matched controls (N:14). 
EXAMPLE 2 
Measuring Levels of Biomarkers 
To measure levels of the protein complex in CSF, a sand 
Wich ELISA has been developed using standard protocols as 
described in Techniques in Molecular Biology and as shoWn 
schematically in FIG. 6. To trap the complex of interest, 
96-Well plates Were coated overnight at 40 C. by adding 200 pl 
1 pg/ml rat anti-human prostaglandin-D-synthase (Cayman 
Chemical, Ann Arbor, Mich. Catalog # 10004342) raised 
against recombinant human prostaglandin-D-synthase in 
PBS containing 0.1% NaN3 (PBSN) per Well. For quanti?ca 
tion, one roW of the plate is coated overnight With puri?ed 
human transferin (Sigma Chemical, St. Louis, Mo.) at 25 
ng/ml, 50 ng/ml, 125 ng/ml, 250 ng/ml, and 500 ng/ml in 
PBSN. After rinsing 5 times With PBSN (200 pl/Wash), the 
plates are blocked for 2 hr With 100 pl 5% dry milk/15% goat 
serum in PBSN. The plates are Washed 5 times With PBST and 
incubated 1 hr at room temperature With 50 pl untreated CSF. 
The plates are Washed 5 times With PBST and are incubated 1 
hr With 1 pg/ml rabbit anti-human transthyretin (Santa CruZ 
Biotechnology, Santa CruZ, Calif.; Catalog # sc-13098) pre 
pared in 5% drymilk/PBSN. The transthyretin antibody is 
raised against amino acids 1-147 presenting full length 
human transthyretin. FolloWing 5 Washes in PBSN the plates 
are incubated With a 1:1000 dilution of horseradish peroxi 
dase conjugated goat anti rabbit IgG (Jackson lmmunore 
search, Laboratories, West Grove, Pa.; Catalog # 1 1 1035003) 
for 1 hr at room temperature. Following 5 Washes in PBST, 
100 pl 3,3',5,5'-tetramethylbenZidine (TMB) color reagent 
(Alpha Diagnostics, San Antonio, Tex.; Catalog # 80091) is 
added to each Well for 30 minutes for color development. The 
reaction is stopped by addition of 50 pl stopping solution 
(Alpha Diagnostics, Catalog # 80100). The plates are read at 
450 nm using a multi-Well plate reader. Blanks for the assay 
consist of all reagents except CSF. Samples are analyZed in 
quadruplicate. To prevent edge effects the outer roWs and 
columns of the plate are not used. Linear calibration curves 
are calculated for each plate and concentrations of CSF deter 
mined. MeanzSEM limits of detection of complexed tran 
sthyretin are 3.6107 ng/ml. MeaniSEM correlation coeffi 
cients for replicate analyses of the calibration curve are 
0.92:0.02 (p<0.01). 
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Complexed transthyretin concentrations (ng/ml CSF) are 
calculated based on the intensity of color developed from the 
horseradish peroxidase labeled secondary antibody and the 
TMB color reagent. The calibration curves constructed for 
each plate demonstrate linearity of response betWeen color 
change as measured by absorbance at 450 nm and concentra 
tion of tranthyretin. The color development only occurs When 
the protein complex is present. For example, if uncomplexed 
prostaglandin-D-synthase is trapped during the initial phase 
of the measurement, it Will not react With the subsequent 
antibody that recogniZes only transthyretin. Antibody speci 
?city Was veri?ed by preincubation of the antibodies With 
immunizing protein or peptide that blocked immunolabeling 
in Western blots. 
Throughout this application, various publications are ref 
erenced. All such publications are hereby incorporated herein 
by reference in their entirety. 
The invention thus being described, it Would be obvious 
that the same may be varied in many Ways. All such variances 
as considered to be embodiments of the present invention and 
not departures therefrom. 
We claim: 
1. A method for aiding diagnosis of mild cognitive impair 
ment or AlZheimer’s Disease in an individual, comprising: 
(a) obtaining a sample of cerebrospinal ?uid from the indi 
vidual; 
(b) measuring an amount of and/or a concentration of a 
protein biomarker complex that comprises transthyretin 
and prostaglandin-H2 isomerase in said sample; and 
(c) comparing the measured amount and/ or concentration 
to a reference value, Wherein a greater measured amount 
and/or concentration of the biomarker complex as com 
pared to the reference value is indicative of a higher 
likelihood that the individual is afflicted with mild cog 
nitive impairment or AlZheimer’s disease, thereby aid 
ing diagnosis of mild cognitive impairment or AlZhe 
imer’s disease in the individual. 
2. The method of claim 1, Wherein the reference value is 
based on a value from each of a plurality of samples, Wherein 
the plurality of samples comprises at least one sample from 
each of a plurality of individuals afflicted with mild cognitive 
impairment or AlZheimer’s disease. 
3. The method of claim 1, Wherein the reference value is 
based on a value from one or a plurality of samples obtained 
from the individual at one or a plurality of earlier points in 
time. 
4. The method of claim 2, Wherein the reference value is 
less than about 5 ng/mL. 
5. The method of claim 2, Wherein the reference value is 
about 5 ng/mL. 
6. The method of claim 2, Wherein the reference value is 5 
ng/mL. 
